Bookmark and Share

David A. Gorelick
 

David A. Gorelick M.D., Ph.D.

Academic Title: Professor
Primary Appointment: Psychiatry
Additional Title(s): Scientific Director, Clinical Neurobehavioral Center
dgorelick@mprc.umaryland.edu
Location: MPRC Tawes Building, E-10
Phone: 410-402-6806
Phone: 667-214-2119
Fax: 410-402-6038
 

Personal History:

Dr. Gorelick is board-certified in psychiatry and addiction medicine and a Distinguished Life Fellow of the American Psychiatric Association.  He has more than 35 years of clinical and clinical research experience in the fields of addiction psychiatry, addiction medicine, and clinical pharmacology, resulting in publication of more than 190 peer-reviewed scientific articles, authorship/co-authorship of more than 50 book chapters, and invited presentations at national and international scientific meetings. He has led inpatient and outpatient addiction treatment programs and designed, conducted, and analyzed phase I and phase II controlled clinical trials.

Dr. Gorelick's research interests are the clinical pharmacology of substance abuse, substance withdrawal, and development of new biological treatments for substance use disorders, including medication, drug-metabolizing enzymes, and transcranial magnetic stimulation (TMS). His recent work focuses on cannabis (marijuana) and the cannabinoid chemicals found in the plant (including their potential therapeutic uses), new medications to treat alcohol and cocaine abuse, and treatment of individuals with both substance use disorders and a comorbid major psychiatric disorder, such as schizophrenia.  Dr. Gorelick is Scientific Director of the Department's Clinical Neurobehavioral Center, where he is conducting outpatient studies of new medication to treat alcohol use disorder.

Dr. Gorelick has an interest in the ethics of clinical research, serving for 10 years as chair of an Institutional Review Board (IRB) that reviewed human research studies, and as a member of the NIH Human Subjects Research Advisory Committee and the NIH Committee on Scientific Conduct and Ethics.

Research Interests:

Clinical pharmacology of substance abuse, substance withdrawal, and biological treatments of substance use disorders, including medication, drug-metabolizing enzymes, and transcranial magnetic stimulation (TMS). Current focus is on cannabis (marijuana), alcohol, and tobacco.


Clinical Specialty:

Dr. Gorelick specializes in addiction psychiatry and addiction medicine.

Publications:

Gorelick DA, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, Kelly DL: Diagnostic criteria for cannabis withdrawal syndrome. Drug and Alcohol Dependence 127:141-147, 2012.

Boggs DL, Kelly DL, Liu F, Linthicum JA, Turner H, Schroeder JR, McMahon RP, & Gorelick DA: Cannabis withdrawal in chronic cannabis users with schizophrenia. Journal of Psychiatric Research, 47(2):240-245, 2013.

Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA: Tolerance to effects of high-dose oral â^?9-tetrahydrocannabinol (THC) and plasma cannabinoid concentrations in male daily cannabis smokers. Journal of Analytical Toxicology, 37(1):11-16, 2013.

Koppelman AM, Gorelick DA, & Appelbaum, PS: Disclosures of conflicts of interest in psychiatric review articles. Journal of Nervous and Mental Disease, 201(2):84-7, 2013.

Chauchard E, Levin KH, Copersino ML, Heishman SJ, & Gorelick DA: Motivations to quit cannabis use in an adult non-treatment sample: Are they related to relapse? Addictive Behaviors, 38:2422-2427, 2013.

Gorelick DA, Goodwin RS, Schwilke E, Schroeder JR, Schwope DM, Kelly DL, Ortemann-Renon C, Bonnet D, & Huestis MA: Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. American Journal on Addictions 22:510-514, 2013.

Fischer BA, McMahon RP, Kelly DL, Wehring HJ, Meyer WA, Feldman S, Carpenter WT, Gorelick DA: Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophrenia Research 161(2-3):471-477, 2015.

Gorelick DA, Zangen A, & George MS: Transcranial magnetic stimulation in the treatment of substance addiction. Annals of the New York Academy of Sciences 1327:79-93, 2014.

Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA: Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug & Alcohol Dependence 144:12-41, 2014.

Gorelick DA & Baumann MH: The pharmacology of cocaine, amphetamines, and other stimulants. In Ries RK, Fiellin DA, Miller SC, & Saitz R (Eds), Principles of Addiction Medicine, 5th edition, (Philadelphia, PA: Wolters Kluwer), 2014, pp. 151-179.

Gorelick DA: Pharmacologic interventions for cocaine, methamphetamine, and other stimulant addiction. In Ries RK, Fiellin DA, Miller SC, & Saitz R (Eds), Principles of Addiction Medicine, 5th edition, (Philadelphia, PA: Wolters Kluwer), 2014, pp. 796-810.